Lexaria Bioscience (LEXX) EBT Margin (2017 - 2025)
Historic EBT Margin for Lexaria Bioscience (LEXX) over the last 12 years, with Q3 2025 value amounting to 1543.55%.
- Lexaria Bioscience's EBT Margin rose 10708200.0% to 1543.55% in Q3 2025 from the same period last year, while for Nov 2025 it was 2061.43%, marking a year-over-year decrease of 5928500.0%. This contributed to the annual value of 1682.58% for FY2025, which is 4465100.0% down from last year.
- As of Q3 2025, Lexaria Bioscience's EBT Margin stood at 1543.55%, which was up 10708200.0% from 2155.31% recorded in Q2 2025.
- Lexaria Bioscience's 5-year EBT Margin high stood at 460.69% for Q1 2024, and its period low was 14434.31% during Q4 2021.
- In the last 5 years, Lexaria Bioscience's EBT Margin had a median value of 1904.81% in 2024 and averaged 2877.33%.
- In the last 5 years, Lexaria Bioscience's EBT Margin tumbled by -141931100bps in 2021 and then soared by 126996000bps in 2022.
- Quarter analysis of 5 years shows Lexaria Bioscience's EBT Margin stood at 14434.31% in 2021, then surged by 88bps to 1734.71% in 2022, then soared by 57bps to 748.17% in 2023, then plummeted by -96bps to 1462.95% in 2024, then decreased by -6bps to 1543.55% in 2025.
- Its last three reported values are 1543.55% in Q3 2025, 2155.31% for Q2 2025, and 1581.04% during Q1 2025.